POST Online Media Lite Edition


Pfizer Q4 revenues down 9%

Christian Fernsby |
Pfizer reported that its fourth quarter adjusted earnings per share declined 13 percent year-over-year to $0.55.

Article continues below

Topics: PFIZER   

On average, 11 analysts polled by Thomson Reuters expected the company to report profit per share of $0.57, for the quarter.

Analysts' estimates typically exclude special items.

Adjusted income declined 17 percent year over year to $3.11 billion.

Fourth-quarter revenues were $12.7 billion, a decline of 9% year on year, reflecting an operational decline of 8%.

Analysts expected revenue of $12.61 billion for the quarter.

Biopharma revenues were $10.5 billion, up 9% operationally.

Fourth quarter Upjohn revenues were $2.2 billion, down 32% operationally, primarily driven by the expected significant volume declines for Lyrica in the U.S.

Excluding the unfavorable impact of Lyrica in the U.S. and other recent product losses of exclusivity, fourth-quarter revenues for Upjohn declined 6% operationally.

For fiscal 2020, Pfizer projects adjusted earnings per share in a range of $2.82 to $2.92; and revenues in a range of $48.5 billion to $50.5 billion.

Analysts polled by Thomson Reuters expect the company to report profit per share of $2.90 on revenue of $49.52 billion.

For New Pfizer, adjusted earnings per share is anticipated to be in a range of $2.25 to $2.35; and revenues are expected to be in a range of $40.7 billion to $42.3 billion.

During 2019, Pfizer returned $16.9 billion directly to shareholders.

As of January 28, 2020, Pfizer's remaining share repurchase authorization was $5.3 billion.

No share repurchases are currently planned in 2020.

What to read next

Elbit Systems Q4 revenues increased to $886.6 million
Pfizer revenues decreased $333 million
Elbit Systems Q4 consolidated results $850.3 million